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Abstract
Aims: Endogenous cardiac progenitor cells, expanded from explants via cardiosphere formation, present a promising cell
source to prevent heart failure following myocardial infarction. Here we used cine-magnetic resonance imaging (MRI) to
track administered cardiosphere-derived cells (CDCs) and to measure changes in cardiac function over four months in the
infarcted rat heart.
Methods and Results: CDCs, cultured from neonatal rat heart, comprised a heterogeneous population including cells
expressing the mesenchymal markers CD90 and CD105, the stem cell marker c-kit and the pluripotency markers Sox2, Oct3/
4 and Klf-4. CDCs (2610
6) expressing green fluorescent protein (GFP+) were labelled with fluorescent micron-sized particles
of iron oxide (MPIO). Labelled cells were administered to the infarcted rat hearts (n=7) by intramyocardial injection
immediately following reperfusion, then by systemic infusion (4610
6) 2 days later. A control group (n=7) was administered
cell medium. MR hypointensities caused by the MPIOs were detected at all times and GFP+ cells containing MPIO particles
were identified in tissue slices at 16 weeks. At two days after infarction, cardiac function was similar between groups. By 6
weeks, ejection fractions in control hearts had significantly decreased (4762%), but this was not evident in CDC-treated
hearts (5663%). The significantly higher ejection fractions in the CDC-treated group were maintained for a further 10 weeks.
In addition, CDC-treated rat hearts had significantly increased capillary density in the peri-infarct region and lower infarct
sizes. MPIO-labelled cells also expressed cardiac troponin I, von Willebrand factor and smooth muscle actin, suggesting their
differentiation along the cardiomyocyte lineage and the formation of new blood vessels.
Conclusions: CDCs were retained in the infarcted rat heart for 16 weeks and improved cardiac function.
Citation: Carr CA, Stuckey DJ, Tan JJ, Tan SC, Gomes RSM, et al. (2011) Cardiosphere-Derived Cells Improve Function in the Infarcted Rat Heart for at Least 16
Weeks – an MRI Study. PLoS ONE 6(10): e25669. doi:10.1371/journal.pone.0025669
Editor: Maurizio Pesce, Centro Cardiologico Monzino, Italy
Received February 11, 2011; Accepted September 9, 2011; Published October 17, 2011
Copyright:  2011 Carr et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the British Heart Foundation (grant number PG/07/059/23259). Dr. Jun Tan and Dr. Suat Tan thank the Malaysian Ministry
of Higher Education for studentships. Dr. Ellison is a recipient of a Marie Curie International Re-integration grant from the FP7 EU Marie Curie Actions (PIRG02-GA-
2007-224853). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Carolyn.Carr@dpag.ox.ac.uk
Introduction
The optimum stem cell for treatment of the infarcted heart has
yet to be established. Despite promising studies using bone marrow
cells in animal models, the results from the clinical trials have not
been conclusive [1], causing a shift in interest to endogenous
cardiac stem cells, which were first identified in 2003 [2,3].
Isolation and culture of these cells from biopsy samples, via the
production of cardiospheres, was reported by Messina et al in 2004
[4]. Further expansion of cardiosphere-derived cells (CDCs) as an
adherent monolayer [5] generated a mixed population, comprising
c-kit+ cardiac progenitor cells and CD90+ cardiac mesenchymal
cells, and provided a sufficient number of cells for therapy within
1–2 months. Promising data from animal studies [5,6] lead to a
clinical trial (CADUCEUS; see ClinicalTrials.gov for details).
However, the characteristics and efficacy of explant-derived cells
(EDCs) has been questioned [7,8,9], with the suggestion that
outgrowth cells from explants were haematological cells [7,9] and
that EDCs were not retained in the heart following administration
[8]. In response, the clonogenicity, multipotency and capacity for
self-renewal of EDCs and CDCs were demonstrated [10,11,12].
Furthermore, improved ejection fraction has been reported in the
infarcted rat heart at 6 weeks after administration of CDCs or
EDCs [12]. As with other stem cell types [13], the observed
improvement in cardiac function with stem cell therapy utilising
cardiac-derived cells has been ascribed both to differentiation of
donor cells, providing new myocytes and blood vessels, and to the
release of paracrine factors, improving cardiomyocyte survival,
activating endogenous cardiac stem cells and angiogenesis [11].
Here CDCs cultured from neonatal rat heart, and characterised
using immunocytochemistry, flow cytometry and quantitative RT-
PCR, were labelled with fluorescent MPIOs and with DiI cell
tracker dye and administered to the infarcted rat heart following
reperfusion. The limited retention of administered cells has beset
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Furthermore, the best mode and timings of injection have yet to be
established. Therefore CDCs were administered twice, by direct
injection at the time of coronary artery ligation and by systemic
infusion after 2 days, thereby maximising the potential of the
CDCs to improve function in the infarcted heart. High resolution
MRI was used to track MPIO-labelled cells and to measure in vivo
cardiac function at baseline and at regular intervals over a long-
term follow up of 4 months following cell administration. Use of a
cardiac progenitor cell, a model of infarction/reperfusion and high
resolution non-invasive MRI, has allowed us to further validate the
potential of CDCs by showing that CDCs are retained in the heart
for at least 16 weeks and we show for the first time that CDC
therapy provides long-term improvement in cardiac function.
Materials and Methods
Animals
Sprague Dawley rats (Harlan, UK) and Sprague Dawley SD-
Tg(GFP)2BalRrrc rats (SD-GFP; Rat Resource and Research
Centre, Missouri) were allowed free access to standard rodent
chow and water throughout the study. All investigations
conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996), the Home Office Guidance
on the Operation of the Animals (Scientific Procedures) Act, 1986
(HMSO), and to institutional guidelines. Approval was granted by
the University of Oxford Animal Ethics Review Committees
and the Home Office (Project Licence numbers 30/2278 and
30/2755).
Rat CDC isolation and culture
Rat CDCs were cultured according to the method of Smith et al
[5]. SD-GFP neonatal rats were sacrificed by cervical dislocation.
Hearts were isolated, washed with Dulbecco’s phosphate buffered
saline (DPBS; Invitrogen) and minced into small explant pieces in
0.05% trypsin-EDTA (Invitrogen). Explants were plated on
fibronectin-coated petri dishes with 1.5 ml of complete explant
medium (CEM) comprising Iscove’s modified Dulbecco’s medium
(IMDM; Invitrogen) supplemented with 20% foetal bovine serum
(FBS; Invitrogen), 1 U/ml penicillin, 1 ug/ml streptomycin and
0.2 mM L-glutamine (Gibco). After 3–4 days in 5% CO2 at 37uC,
small, round, phase bright cells grew out from the explants over a
bed of stromal-like cells. Once they reached 80–90% confluency,
these explant-derived cells (EDCs) were isolated using trypsin and
re-plated on poly-d-lysine coated 24 well plates in cardiosphere
growth medium (CGM) comprising 65% Dulbecco’s modified
eagle medium (DMEM/F12), 35% IMDM, 7% FBS, 2% B27
(Invitrogen), 25 ng/ml cardiotrophin (Peprotech EC), 10 ng/ml
epidermal growth factor (EGF; Peprotech EC), 20 ng/ml basic
fibroblast growth factor (FGF; Promega) and 5 units thrombin
(Sigma). EDCs could be harvested every 7 days, for up to 4 weeks.
Cardiospheres formed after 2–3 days, when they were harvested
by mechanical trituration and plated in CEM in fibronectin-
coated flasks. Cardiosphere-derived cells (CDCs) were passaged
every 5–7 days to passage 2. Secondary cardiospheres could be
formed by replating CDCs in CGM in poly-lysine coated 24 well
plates.
CDC labelling
CDCs were incubated overnight with micron-sized particles of
iron oxide (MPIO; 2 ml/cm
2, encapsulated magnetic micro-
spheres, Bangs Laboratories Inc.), on the day prior to transplan-
tation. Viability and proliferation of MPIO-labelled CDCs was
measured over 3 days using the LIVE/DEAD cell cytotoxicity kit
(Molecular Probes). For the in vivo study, MPIO-labelled CDCs
were washed twice with PBS and stained with DiI (Molecular
Probes) in PBS for 30 minutes before trypsinization. Approxi-
mately 2610
6 cells were suspended in 50 ml CEM for direct
injection to the myocardium and 4610
6 cells were suspended in
500 ml CEM for systemic infusion. For MR microscopy, MPIO-
labelled CDCs were suspended in 1% agarose doped with
gadolinium DTPA (4 ml/ml).
CDC differentiation into cardiomyocytes
CDCs were plated in 6 well plates coated with 0.1% gelatin at a
density of 10,000 cells/cm
2 and incubated overnight in CEM.
Medium was changed to differentiation medium (45% IMDM,
45% DMEM, 10% ESQ FBS (Invitrogen), Insulin-transferrin-
selenium (16; Invitrogen) and 300 mM ascorbic acid) for 6–
8 hours, followed by incubation with differentiation medium
containing 1 mM dimethyl sulphoxide (DMSO) for 10 days, with
fresh medium added every 2 days.
Characterisation of CDCs using qRT-PCR
Primers were designed using Primer3 software based on
interpretation of GenBank or Ensembl Genome Browser search
results and are listed in File S1. Total RNA was extracted using
Trizol (Sigma) and treated with Turbo DNA-free (Ambion).
Complementary DNA (cDNA) was synthesized from the treated
RNA template using AB high capacity transcriptase kit (Applied
Biosystem). Real time PCR amplification was performed (AB
StepOnePlus Real-Time, CA) and all data were analyzed using the
published 2
2DDCt method [14] with the StepOne modification
where the amplification efficiencies of the target and reference
genes were not equal. Relative mRNA levels were normalized to
GAPDH and expressed relative to neonatal whole heart total
RNA. Further details are provided in File S1.
Characterisation of CDCs using immunocytochemistry
Cells (8610
4/80 ml) cultured on chamber slides were fixed with
4% PFA on ice for 20 minutes. For intracellular staining, cells
were permeabilized with 0.1% triton X in PBS for 10 minutes.
This step was omitted for cytoplasmic staining. Then cells were
blocked with 10% donkey serum for 30 minutes and stained with
primary antibody (see File S1) overnight at 4uC. After rinsing, cells
were labelled with secondary antibody for one hour at 37uC,
counterstained with 49,6-diamidino-2-phenylindole (DAPI, Sigma)
and mounted with VECTASHIELDH mounting medium. Nega-
tive control staining was performed whereby the primary antibody
was omitted. Immunostaining was visualized and analyzed using
laser scanning confocal microscopy (Zeiss LSM510 and LSM710
Meta laser confocal microscope). For quantification of cardiac
troponin I (cTnI) staining, the percentage of positively stained cells
was counted in 18 representative fields from 3 experiments (at
4006magnification).
Rat myocardial infarction and CDC administration
The left anterior descending (LAD) coronary artery of female
SD rats (200–250 g, n=14) was occluded using the method of
Michael et al [15]. In brief, following anaesthesia, using 2%
isoflurane in O2, and thoracotamy, the pericardium was removed
and a 5-0 prolene suture placed under the LAD, about 2 mm from
the origin. The suture was tied around a small piece of PE tubing,
occluding the LAD, and the chest closed. After 50 minutes, the
chest was re-opened and the tubing removed to allow reperfusion.
Ten minutes after ischaemia/reperfusion, CDCs (2610
6 in 50 ml
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Control group) were injected over four sites in the peri-infarct
region. Two days after MI, a bolus of CDCs (4610
6 in 500 ml
CEM) or medium (500 ml CEM) was administered via the tail vein
to the CDC-treated and control group, respectively. In sham
animals (n=3), the thoracotamy was performed but no stitch
placed in the heart.
Cardiac cine MRI
Cardiac cine MRI was performed as previously described [16].
Briefly, rats were anaesthetised with 2.5% isoflurane in O2,
positioned supine in a purpose built cradle and lowered into a
60 mm birdcage coil in a vertical bore 500 MHz, 11.7 T MR
system with a Bruker console running Paravision 2.1.1. A stack of
7–8 contiguous 1.5 mm true short axis ECG-gated cine images
were acquired to cover the entire left ventricle. The epicardial and
endocardial borders were outlined in end diastolic and systolic
frames using the freehand drawing tool in Image J [17]. Cardiac
mass and left ventricular volumes were summed over the whole
heart. Further details are provided in File S1. Animals were
sacrificed by overdose of pentobarbitone after the final MR images
were acquired.
High resolution 3D MR microscopy
Hearts (n=4; 2 hearts from each group) were isolated and fixed
in 4% (w/v) paraformaldehyde (Sigma, UK) in phosphate buffered
saline (pH 7.2) and embedded in 1% (w/v) agarose doped with
gadolinium DTPA in a 20 mm NMR-tube. High-resolution MRI
was performed in a 20 mm quadrature-driven birdcage coil
(Rapid Biomedical, Wu ¨rzburg, Germany) using a fast gradient
echo sequence (see File S1 for details).
Histological analysis
Infarcted hearts (n=10; 5 hearts from each group) were
isolated, cut into basal and apical halves and frozen in OCT
(Tissue-Tek) over dry ice. Frozen sections were cut into serial
10 mm slices and stained with or picro-Sirius Red. The amount of
positive staining was quantified using ImagePro Plus 5.0
(MediaCybernetics Inc, Bethesda, Md) image analysis software.
Infarct volume was calculated by multiplying the area of infarcted
tissue in each tissue slice by the distance between those slices in the
heart (1.5 mm).
Immunohistochemistry
Capillary density. In a humidity chamber, tissue sections
were fixed in 4% paraformaldehyde for 10 minutes at room
temperature, washed and permeabilized with 0.5% Triton for
10 minutes at room temperature. Sections were incubated for
20 minutes with diluted normal mouse blocking serum and then
with PECAM-1/CD31 mouse anti-rat (AbD Serotec,
MCA1334G; 1:100 dilution), for 1 hour at room temperature.
The sections were washed and incubated with biotinylated anti
mouse secondary antibody (Vectastain ABC kit; Vector
Laboratories, PK-4002) for 30 minutes at room temperature,
followed by incubation with DAB Perosidase Substrate kit (Vector
Laboratories, SK-4100) for 10 minutes and mounting. Images
were acquired on 610 magnification with a GETI light
microscope connected to Cannon Digital camera. CD31 was
quantified using ImageJ.
Cell characterization. Frozen tissue sections were fixed
using ethanol-glycine fixative for 20 minutes at room temperature
and blocked with 10% donkey serum in PBS for 30 minutes.
Tissue sections were incubated with primary antibody (see File S1)
at 4uC overnight. After rinsing, tissue was labelled with secondary
antibody for 1 hour, counterstained with DAPI and mounted with
VECTASHIELDH mounting medium. Negative control staining
was performed whereby the primary antibody was omitted.
Immunostaining was visualized and analyzed using laser
scanning confocal microscopy (Zeiss LSM510 and LSM710
Meta laser confocal microscope). The proportion of cells labelled
with MPIO that also stained for cTnI, SMA or vWF was
quantified in the infarct/peri-infarct region of the heart from at
least 10 representative fields from 3 hearts (at 636magnification).
A capillary was defined as 1 or 2 endothelial cells spanning the
vWF-positive vessel circumference. An arteriole was defined as 2
or more SMA positive cells spanning the vessel circumference.
Statistical analysis
Results are presented as means 6 standard errors. Differences
were considered significant at p,0.05, determined using analysis
of variance with a post hoc t-test with Tukey correction or a
Student’s t-test (SPSS).
Results
CDC culture and characterisation
Explant-derived cells (EDCs) were harvested and cultured to
form cardiospheres, which were then expanded as a monolayer
culture to passage 2 (p2) as CDCs within 3–4 weeks of biopsy.
Flow cytometry revealed that 3.060.1% of p2 CDCs expressed
the stem cell marker c-kit, 7167% expressed CD90 and 1062%
expressed the fibroblast marker, DDR2 (Figure 1A & 1B),
indicating a largely mesenchymal cell population (figure S1). Less
than 1% of CDCs expressed CD45 (data not shown). Gene
expression was analysed using quantitative RT-PCR and ex-
pressed relative to expression in neonatal rat heart (Figure 1C).
CDCs expressed c-kit, the cardiac transcription factor GATA-4
and the glycoprotein CD105 (4.160.3%, 10.260.7% and
42617% of that in neonatal heart, respectively) with high levels
of CD90 (1461 fold higher than in neonatal heart.
Using immunocytochemistry, cells were found to express the
pluripotency markers, Oct3/4, Sox2, and Klf-4, with little or no
expression of Nanog (Figure 1D). In line with the flow cytometry
data, immunocytochemistry showed that approximately 2% of
CDCs expressed c-kit (Figure 1D). Cardiosphere-derived cells
expressed the cardiac transcription factors, GATA-4 and Nkx2.5
indicative of their origin and also showed multipotency through
spontaneous differentiation into the three main cardiac lineages;
endothelial (positive for von Willibrand factor (vWF)), smooth
muscle (positive for a-smooth muscle actin (SMA)) and cardiomy-
ocyte (positive for a-sarcomeric actin) (Figure 1D). Cycling cells
were detected by staining for Ki67 (Figure 1D). CDCs cultured to
full confluency showed increased expression of a-sarcomeric actin
and began to express cardiac troponin T (figure S2). Culture in
differentiation medium containing DMSO for 10 days promoted
CDC differentiation further along the cardiomyocyte lineage,
detected by immunostaining for cardiac troponin T and increased
mRNA expression of Nkx2.5, cardiac troponin T and myosin
heavy chain. (Figure 1E and Figure S2). Cells treated with DMSO
began to adopt an elongated morphology more indicative of a
cardiomyocyte and to show striations not evident in the cells
cultured beyond confluency (figure S2).
Although the CD90+ population may include cardiac fibro-
blasts [7], only 10% of CDCs expressed the fibroblast marker
DDR2 [18] and the detection of Oct 3/4, Sox2 and Klf-4
confirmed the presence of pluripotent stem cells within the CDC
population. Furthermore, treatment with DMSO induced differ-
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CD90 and DDR2, representative plots are shown in (A) and quantication in (B); (C) qRT-PCR for c-kit, GATA-4, CD105 and CD90, expressed relative to
100% expression in neonatal heart and normalised to GAPDH; and (D) immunocytochemistry for Oct3/4, Sox2, Nanog, KLF-4, c-kit, GATA-4, Nkx2.5,
von Willibrand factor (vWF), a–smooth muscle actin (a–SMA), a–sarcomeric actin and Ki67. (E & F) Incubation with DMSO for 10 days promoted
differentiation along the cardiac lineage as shown by increased protein expression of cTroponin I (E: green) and mRNA expression of Nkx2.5, Troponin
T and myosin heavy chain (MyHC) (F).
doi:10.1371/journal.pone.0025669.g001
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(1966%) than the proportion of c-kit+ cells present (3.060.1%)
suggesting that the CDC population contains a c-kit negative
population of cells capable of differentiation into cardiomyocytes.
MPIO labelling
The viability of the CDCs was not altered after labelling with
fluorescent microparticles of iron oxide (MPIO; Figure 2A).
MPIO-labelled cells formed secondary cardiospheres (Figure 2B)
and proliferated at a rate comparable with unlabelled CDCs
(Figure 2C). MPIO-labelled CDCs were imaged using MR with a
4610
6 voxels/ml resolution. It was found that 10
5 labelled cells,
suspended in 0.6 ml agarose, caused a large signal void
(Figure 2D). When only 1% of the 10
5 CDCs were MPIO-
labelled, small regions of signal void were detected throughout the
phantom, indicating that the labelled cells could be detected with
single cell resolution.
Cardiac function
Cine-MRI was used to measure cardiac morphology and
function at baseline (2 days post MI) and at 2, 6, 10 and 16 weeks
after MI and the administration of CDCs (Figure 3). At baseline,
there were no significant differences between control and CDC-
treated hearts in ejection fraction (EF), end diastolic volume
(EDV), end systolic volume (ESV), stroke volume (SV) or cardiac
output (CO) (see Figure 3 and table S1). In control hearts, cardiac
remodelling resulted in a significant decrease in EF between
baseline and 2 weeks and again between 2 and 6 weeks, such that,
by 6 weeks, control heart EF had decreased by 13% (EF 4762%,
p,0.05 vs. baseline) and was significantly lower than that of CDC-
treated hearts (EF 5663%, p,0.05 vs. control). This 9%
difference in ejection fraction was maintained to 16 weeks post
MI such that the ejection fractions of CDC-treated hearts were not
significantly different from shams (EF sham 6762%; control
4763% p,0.05 vs sham; CDC 5763%, p,0.05 vs control, ns vs
sham; Figure 3). Although both control and CDC-treated hearts
showed significant dilation by two weeks, the end systolic volume
of the CDC-treated hearts was significantly smaller at 2 weeks
than that of the control hearts (ESV sham 7669m m
3, control
247627 mm
3,p ,0.05 vs sham; CDC 177613 mm
3,p ,0.05 vs
sham and control). Further remodelling was attenuated in CDC-
treated hearts, compared with control hearts, such that at later
time points end systolic volumes of control hearts, but not of CDC-
treated hearts, were significantly larger than those of shams
(Figure 3). Relative infarct size (measured as the area of the
myocardial wall that was akinetic) was the same in all infarcted
hearts at 2 days (control 2464m m
2,9 61% of LV wall, CDC-
treated 2464m m
2,9 62%), and by 10 weeks had increased
significantly in control hearts but not in CDC-treated hearts
(control 5664m m
2,1 5 62%, p,0.05 vs baseline; CDC-treated
3864m m
2,1 2 62%, ns vs baseline; Figure 3). At 16 weeks, the
infarct size in CDC-treated hearts was significantly lower than that
in control infarcted hearts (control 6169m m
2,1 6 62%, CDC-
treated 3667m m
2,1 0 61%, p,0.05 vs control; Figure 3). End
systolic posterior wall thickness was comparable between the three
groups. At 2 and 6 weeks, the peri-infarct wall at end-systole was
significantly thinner than at baseline in both infarct groups,
however by 10 weeks CDC treatment had restored the wall
thickness such that the peri-infarct region in the CDC-treated
group was significantly thicker at end systole than that in the
control group (control 2.160.04 mm, CDC 2.560.1 mm, p,0.05
vs control; Figure 3).
CDC Retention and cardiac morphology
Hypointensities caused by the MPIO particles were detected at
all times in the infarct region of CDC-treated hearts using in vivo
Figure 2. CDCs were not adversely affected by labelling with MPIOs and could be detected using MR microscopy. (A) CDCs
endocytosed fluorescent MPIOs during overnight incubation; (B) MPIO-labelled CDCs retained the ability to form cardiospheres; (C) live (blue) and
dead (red) cell numbers were comparable between unlabelled and MPIO-labelled CDCs; (D) MPIO-labelled CDCs could be detected at the single cell
level (10
3 cells / 0.5 ml, arrows) using MR microscopy.
doi:10.1371/journal.pone.0025669.g002
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using ex vivo microscopy (Figure 4A). The dragon green
fluorescence of the MPIOs was clearly detected in tissue slices
(Figures 4B–D, 5A–D). Donor cells expressing GFP were detected
using antibody labelling, which co-localised with detection of
fluorescence from the MPIOs (Figure 4B and Figure S3).
Furthermore, although macrophages were detected in tissue slices,
by antibody labelling for CD68, they were not labelled with the
MPIOs (Figure 4C), showing that MPIO-labelled CDCs survived
in the myocardium at 16 weeks and neither they nor the iron
particles had been taken up by the infiltrating macrophages. Cells
labelled both with MPIOs and with DiI were located in
abundance in the fibrotic region of the scar, in the epicardium
and, more rarely, in remote myocardium. MPIO-labelled CDCs
were not positive for vimentin and therefore the cells did not
appear to be myofibroblasts (Figure 4D). Regenerating myocardial
cells were detected by co-localisation of immuno-staining for cTnI,
vWF, and SMA with MPIO and DiI labelling (Figure 5A–D).
4963% of MPIO-labelled cells in the infarct/peri-infarct region
also expressed cTnI (Figure 5A & D), 1263% in vWF-positive
capillaries (Figure 5B) and 862% were detected in SMA-positive
arterioles (Figure 5C). The MPIO/cTnI double positive cells
remained small in size, indicative of a not fully matured CDC-
derived cardiomyocyte. Although these immature cardiomyocytes
expressed a small amount of connexin 43, these were not in
connection with neighbouring and survived myocytes and
therefore no gap junctions were formed (Figure 5D). Infarct size
was measured using MR and by histological staining of tissue slices
taken to corresponded with the position of the MR imaging slices
(Figure 6A). Collagen density, measured using picro-Sirius Red
staining, correlated with the size of the akinetic region of the
myocardial wall measured in the in vivo MR images (Figure 6B).
Collagen density was reduced by 40% (p,0.05) in CDC-treated
hearts compared with untreated control hearts (Figure 6C).
Capillary density, measured using immuno-staining for CD31
(Figure 6D), was increased by 44% (p,0.05) in the peri-infarct
region of CDC-treated hearts compared with control hearts
(Figure 6E). In summary, CDCs were retained in the infarcted rat
heart for at least 16 weeks, increased ejection fraction and capillary
density, and ameliorated the increase in end systolic volume and
relative infarct size compared with untreated infarcted rat hearts.
Discussion
Here, we have used MRI to show for the first time that cardiac
function was improved and maintained over long-term follow-up
in the rat heart following ischaemia/reperfusion and cardiosphere-
derived cell therapy.
Figure 3. CDC administration improved cardiac function. Cardiac ejection fraction, end systolic volume, end diastolic volume, stroke volume,
relative infarct size and end-systolic peri-infarct thickness, measured over 16 weeks using MRI, showed that cardiac function in the infarcted hearts
was improved by administration of CDCs. * p,0.05 vs sham ; # p,0.05 vs control; { p,0.05 vs 2 days (shown only for infarct size and peri-infarct
thickness for clarity).
doi:10.1371/journal.pone.0025669.g003
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c-kit+/CD105+ cardiac progenitor cells, CD90+/CD105+ cardiac
mesenchymal cells and CD31+/CD34+ endothelial cells [10].
Andersen et al [7] suggested that cells cultured using the explant
protocol comprise a mixture of fibroblasts and blood-borne cells,
however we found that less than 10% of cells expressed the
fibroblast marker DDR2 [18] and less than 1% were CD45+
haematopoietic cells. CDCs from neonatal rat heart were cultured
to p2 within one month of biopsy. The percentage of c-kit+ cells at
p2 was lower than reported by Smith et al [5], with mRNA
expression comparable with that shown by Andersen et al [7].
Nevertheless, cells expressing the pluripotent markers Oct3/4 and
Sox-2 were detected within the CDC population. Li et al reported
that cardiosphere culture increased expression of Sox-2 and
Nanog in human CDCs but that this expression was lower after 3
days of monolayer culture [19]. Furthermore, GATA-4 high c-kit+
cardiac stem progenitor cells (CSCs), which are committed to the
cardiomyocyte lineage and show enhanced cardiomyocyte differ-
entiation, have decreased cardiosphere generation capability,
compared to GATA-4 low c-kit+ CSCs, which consist of more
primitive (Oct-4 and Sox-2 positive) stem cells [20] . The
expression of the pluripotent markers, Oct-4 and Sox-2, and the
cardiac transcription factors, GATA-4 and Nkx2.5, in CDCs was
heterogeneous, but evident in the majority of the cells (Figure 1).
Down-regulation of the pluripotent markers is required for the
cells to commit to the cardiac lineage, when there is an up-
Figure 4. MPIO-labelled CDCs were tracked in vivo and identified in tissue sections. A: Regions of hypointensity due to MPIOs (arrows)
were detected in CDC-treated hearts using in vivo MRI for 16 weeks after administration, and confirmed using ex vivo MR microscopy (example
images from the same heart at 2 days, 2 weeks and 16 weeks are shown, in vivo top, left & right, bottom left, ex vivo bottom right). B: In tissue slices,
MPIOs (green) were shown to co-localise with expression of GFP (magenta). C: Macrophages were detected in tissue slices, by antibody labelling for
CD68 (magenta, yellow arrowheads), but were not labelled with DiI (red) or MPIOs (green, white arrows). D: No vimentin positive/MPIO/DiI positive
cells were observed and therefore the cells did not appear to be myofibroblasts.
doi:10.1371/journal.pone.0025669.g004
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GATA-4 [21].
Treatment of CDCs with DMSO for 10 days promoted
expression of cTnT, Nkx2.5 and myosin heavy chain, demon-
strating their ability to differentiate into more mature myocyte
precursors. Finally, the detection of a-smooth muscle actin, von
Willibrand factor and a-sarcomeric actin suggested that CDCs
contained cells capable of forming all three cardiac lineages. MRI,
the gold standard for clinical measurement of cardiac function
[22], produces accurate, reproducible measurements of cardiac
function in rodents [23] and, in concert with iron oxide labelling of
cells, can be used to demonstrate the success of donor cell
administration and cell retention [24]. The validity of cell tracking
using iron oxide has been questioned, as in vivo studies identified
iron oxide nanoparticles in macrophages and not in the
administered cells [25]. However, larger MPIOs were retained
in administrated cells in vivo for 3 weeks in CDCs [26] and for 16
weeks in bone marrow cells [24,27]. Here, MPIOs were found to
co-localise with DiI labelling, and expression of GFP confirmed
that the majority of the MPIOs were retained within the donor
cells 16 weeks after administration. Furthermore, although
macrophages were detected in tissue slices, they did not co-localise
with the MPIO particles. The MPIOs used here were encapsu-
lated in a polymer which made the surface of the particle free of
iron oxide. It may be that these larger, encapsulated particles are
retained within the cell more successfully than iron oxide
nanoparticles.
The reperfused heart is more appropriate and applicable for
pre-clinical studies where cells are administered shortly after
infarction. Although human myocardial infarction is followed by
reperfusion of the occluded vessel using thrombolytics and/or
percutaneous coronary intervention [28,29], most studies of stem
cell therapy in rodents still use total occlusion of the coronary
artery [5]. The infarct region following reperfusion differs
substantially from that following total occlusion [30]. Reperfusion
results in decreased infarct size and reduced remodelling [31], but
Figure 5. Differentiating CDCs were detected in tissue sections. Regenerating myocardial cells were detected by co-localisation of MPIO
(green) and DiI (red) labelling with (A) immuno-staining for cTnI (magenta); (B) vWF-positive capillaries (magenta) and (C) SMA-positive arterioles
(magenta, inset is at 62 zoom), indicating de-novo cardiomyocyte and vessel formation from administered CDCs. (D) MPIO/cTnI positive small
immature cells within the border zone expressed a small amount of connexin 43 (arrow), but these cells did not form gap junctions with mature
cardiomyocytes.
doi:10.1371/journal.pone.0025669.g005
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cause myocyte necrosis [32]. As a result, the peri-infarct
environment differs substantially between the two infarct models.
The increased inflammatory reaction immediately following
reperfusion may result in clearance of administered donor cells
from the peri-infarct region. Therefore, CDCs were also delivered
by systemic infusion after two days, when the initial inflammatory
influx would have subsided [32].
Here in vivo cine MRI provided extensive characterisation of
cardiac function in the rat heart immediately after ischaemia/
reperfusion and at four time points over the subsequent 16 weeks.
Conflicting reports of the efficacy of endogenous cardiac cells
cultured from tissue explants may be ascribed to differences in
techniques and species. Intracoronary administration of 3610
6
porcine CDCs reduced infarct size and improved haemodynamic
function in the pig heart 8 weeks after balloon occlusion and
reperfusion [6], yet there was no improvement in ejection fraction.
After injection of EDCs, expanded without forming cardiospheres,
Li et al [8] observed no difference in cardiac function,
haemodynamics or infarct size at 8 weeks between untreated
mouse hearts and those injected with 5610
5 cells. In vivo
bioluminescent imaging showed poor donor cell survival by 8
weeks. In contrast, also in the mouse, Davis et al [12] reported a
9% improvement in ejection fraction, measured using MRI, at 3
and 6 weeks after administration of 1610
6 EDCs and Chimenti
et al [11] reported a 16% increase in ejection fraction, measured
using 2D echocardiography, at three weeks after administration of
1610
5 CDCs. The significant progressive decline in cardiac
function we observed in untreated infarcted rat hearts, shown by
significantly decreased ejection fraction and increased end systolic
volume, was prevented by CDC administration. Accurate
measurement of cardiac morphology showed that the systolic wall
thickness of the peri-infarct region was comparable in both groups
at 2 weeks, but by 10 weeks CDC treatment had restored wall
thickness in this region. This may have resulted from the CDC-
derived cardiomyocytes, increased capillary density and reduced
fibrosis in treated hearts, as also reported by others [11].
The administered CDCs were predominantly localised within
the fibrotic regions of the infarct. MPIO- and DiI-labelled cells
expressing cTnI, vWF and SMA were detected in the infarct and,
more rarely, in the remote myocardium, indicating differentiation
of CDCs along the cardiomyocyte lineage and, less frequently, the
formation of new blood vessels. However, less than half of the
labelled cells within the infarct/peri-infarct region expressed cTnI
and these cells were also small in size, suggesting an immature,
fetal phenotype. Therefore, the major contribution to the observed
long-term improvement in cardiac function most likely resulted
from increased paracrine factors that reduced fibrosis and
increased capillary density in CDC-treated hearts. Human CDCs
secrete vascular endothelial growth factor, hepatocyte growth
factor (HGF) and insulin-like growth factor 1 (IGF-1) leading to
increased capillary density in the mouse heart 3 weeks after CDC
administration [11]. Moreover, administration of HGF and IGF-1
to the infarcted pig heart resulted in activation and differentiation
of endogenous c-kit
+ cardiac stem cells as well as improved
cardiomyocyte survival, and reduced fibrosis and cardiomyocyte
hypertrophy [33]. Further investigation is warranted to identify
factors and conditions that promote the maturation of the CDC-
derived cardiomyocytes to a mature and functional phenotype
within the infarcted region.
Despite producing a CDC population containing about 30%
more CD90+ cardiac mesenchymal cells and 12% fewer c-kit+
cardiac progenitor cells than others [5], we found that a single
injection of 2610
6 CDCs 10 minutes post ischaemia/reperfusion
MI and a further bolus of 4610
6 CDCs administered systemically
2 days later, homed to the infarcted myocardium and were
retained at 16 weeks follow-up. A significant proportion of CDCs
differentiated towards the cardiomyocyte lineage. We also found
lower fibrosis and increased capillary density at 16 weeks,
suggesting the release of paracrine factors by the transplanted
CDCs. Importantly, these changes resulted in improved cardiac
function at 4 months, which was not evident in the control group
that did not receive CDC treatment. Thus, cardiosphere-derived
cells may be expanded from biopsy samples to provide a cell
Figure 6. CDC administration reduced infarct size and increased capillary density. Infarct size measurements obtained using picro-Sirius
red staining (A: top) and MRI (A: bottom) were found to correlate (B) and showed that CDC-treated hearts were less fibrotic than control hearts (C).
Immuno-staining for CD31 showed increased capillary density in the peri-infarct region of CDC-treated hearts compared with controls; representative
images are shown in (D) and quantified in (E).
doi:10.1371/journal.pone.0025669.g006
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infarcted heart.
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spontaneously differentiating cells, detected by staining for cTnI.
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Figure S2 CDCs cultured to confluency (middle panels)
showed spontaneous differentiation with expression of
cTroponin T and a-sarcomeric actin, which were not
seen in non-confuent CDCs (top panels). Culture in
differentiation medium containing DMSO (bottom panels)
resulted in cells adopting an elongated morphology more
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Figure S3 Detection of GFP-expressing cells labelled
with DiI and MPIOs confirmed that administered cells
were retained in the hearts after 16 weeks; the white
arrows identify double stained GFP+ MPIO+ CDCs,
whilst the yellow arrowheads identify GFP+ CDCs alone.
(PDF)
Table S1 Cardiac function and morphology measured
over 16 weeks using MRI.
(PDF)
Acknowledgments
The authors would like to thank Dr. Cesare Terracciano, Imperial College,
for the generous gift of breeding pairs of SD-GFP rats.
Author Contributions
Conceived and designed the experiments: CAC DJS EM AG GME KC.
Performed the experiments: CAC DJS JJT SCT RMSG PC GME.
Analyzed the data: CAC DJS JJT SCT RMSG GME. Contributed
reagents/materials/analysis tools: CAC DJS GME KC. Wrote the paper:
CAC DJS EM GME KC.
References
1. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, et al. (2008)
Autologous bone marrow stem cells to treat acute myocardial infarction: a
systematic review. Eur Heart J 29: 1807–1818.
2. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, et al. (2003) Adult
cardiac stem cells are multipotent and support myocardial regeneration. Cell
114: 763–776.
3. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, et al. (2003)
Cardiac progenitor cells from adult myocardium: homing, differentiation, and
fusion after infarction. Proc Natl Acad Sci U S A 100: 12313–12318.
4. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, et al. (2004) Isolation
and expansion of adult cardiac stem cells from human and murine heart. Circ
Res 95: 911–921.
5. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, et al. (2007) Regenerative
potential of cardiosphere-derived cells expanded from percutaneous endomyo-
cardial biopsy specimens. Circulation 115: 896–908.
6. Johnston PV, Sasano T, Mills K, Evers R, Lee ST, et al. (2009) Engraftment,
differentiation, and functional benefits of autologous cardiosphere-derived cells
in porcine ischemic cardiomyopathy. Circulation 120: 1075–1083, 1077 p
following 1083.
7. Andersen DC, Andersen P, Schneider M, Jensen HB, Sheikh SP (2009) Murine
‘‘cardiospheres’’ are not a source of stem cells with cardiomyogenic potential.
Stem Cells 27: 1571–1581.
8. Li Z, Lee A, Huang M, Chun H, Chung J, et al. (2009) Imaging survival and
function of transplanted cardiac resident stem cells. J Am Coll Cardiol 53:
1229–1240.
9. Shenje LT, Field LJ, Pritchard CA, Guerin CJ, Rubart M, et al. (2008) Lineage
tracing of cardiac explant derived cells. PLoS ONE 3: e1929.
10. Davis DR, Zhang Y, Smith RR, Cheng K, Terrovitis J, et al. (2009) Validation
of the cardiosphere method to culture cardiac progenitor cells from myocardial
tissue. PLoS ONE 4: e7195.
11. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, et al. (2010) Relative
roles of direct regeneration versus paracrine effects of human cardiosphere-
derived cells transplanted into infarcted mice. Circ Res 106: 971–980.
12. Davis DR, Kizana E, Terrovitis J, Barth AS, Zhang Y, et al. (2010) Isolation and
expansion of functionally-competent cardiac progenitor cells directly from heart
biopsies. J Mol Cell Cardiol 49: 312–321.
13. Shintani Y, Fukushima S, Varela-Carver A, Lee J, Coppen SR, et al. (2009)
Donor cell-type specific paracrine effects of cell transplantation for post-
infarction heart failure. J Mol Cell Cardiol 47: 288–295.
14. Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation
of real-time quantitative reverse transcriptase-polymerase chain reaction for
monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:
41–49.
15. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, et al. (1995)
Myocardial ischemia and reperfusion: a murine model. Am J Physiol 269:
H2147–2154.
16. Tyler DJ, Lygate CA, Schneider JE, Cassidy PJ, Neubauer S, et al. (2006) CINE-
MR imaging of the normal and infarcted rat heart using an 11.7 T vertical bore
MR system. J Cardiovasc Magn Reson 8: 327–333.
17. Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image Processing with ImageJ.
Biophotonics International 11: 36–42.
18. Camelliti P, Borg TK, Kohl P (2005) Structural and functional characterisation
of cardiac fibroblasts. Cardiovasc Res 65: 40–51.
19. Li TS, Cheng K, Lee ST, Matsushita S, Davis D, et al. (2010) Cardiospheres
recapitulate a niche-like microenvironment rich in stemness and cell-matrix
interactions, rationalizing their enhanced functional potency for myocardial
repair. Stem Cells 28: 2088–2098.
20. Miyamoto S, Kawaguchi N, Ellison GM, Matsuoka R, Shin’oka T, et al. (2009)
Characterization of Long-Term Cultured c-kitpos Cardiac Stem Cells (CSCs)
Derived from Adult Rat Hearts. Stem Cells Dev.
21. Graf T, Stadtfeld M (2008) Heterogeneity of embryonic and adult stem cells.
Cell Stem Cell 3: 480–483.
22. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S (2009)
The role of cardiovascular magnetic resonance imaging in heart failure. J Am
Coll Cardiol 54: 1407–1424.
23. Stuckey DJ, Carr CA, Tyler DJ, Clarke K (2008) Cine-MRI versus two-
dimensional echocardiography to measure in vivo left ventricular function in rat
heart. NMR Biomed 21: 765–772.
24. Stuckey DJ, Carr CA, Martin-Rendon E, Tyler DJ, Willmott C, et al. (2006)
Iron particles for noninvasive monitoring of bone marrow stromal cell
engraftment into, and isolation of viable engrafted donor cells from, the heart.
Stem Cells 24: 1968–1975.
25. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, et al. (2007) Iron-
oxide labeling and outcome of transplanted mesenchymal stem cells in the
infarcted myocardium. Circulation 116: I38–45.
26. Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, et al. (2010) Magnetic
targeting enhances engraftment and functional benefit of iron-labeled cardio-
sphere-derived cells in myocardial infarction. Circ Res 106: 1570–1581.
27. Carr CA, Stuckey DJ, Tatton L, Tyler DJ, Hale SJ, et al. (2008) Bone marrow-
derived stromal cells home to and remain in the infarcted rat heart but fail to
improve function: an in vivo cine-MRI study. Am J Physiol Heart Circ Physiol
295: H533–542.
28. Neuzil J, Rayner BS, Lowe HC, Witting PK (2005) Oxidative stress in
myocardial ischaemia reperfusion injury: a renewed focus on a long-standing
area of heart research. Redox Rep 10: 187–197.
29. Levitsky S (2006) Protecting the myocardial cell during coronary revasculari-
zation. The William W. L. Glenn Lecture. Circulation 114: I339–343.
30. De Celle T, Cleutjens JP, Blankesteijn WM, Debets JJ, Smits JF, et al. (2004)
Long-term structural and functional consequences of cardiac ischaemia-
reperfusion injury in vivo in mice. Exp Physiol 89: 605–615.
31. de Boer MJ, Suryapranata H, Hoorntje JC, Reiffers S, Liem AL, et al. (1994)
Limitation of infarct size and preservation of left ventricular function after
primary coronary angioplasty compared with intravenous streptokinase in acute
myocardial infarction. Circulation 90: 753–761.
32. Frangogiannis NG, Smith CW, Entman ML (2002) The inflammatory response
in myocardial infarction. Cardiovasc Res 53: 31–47.
33. Ellison GM, Torella D, Dellegrottaglie S, Perez-Martinez C, Perez de Prado A,
et al. (2011) Endogenous cardiac stem cell activation by insulin-like growth
factor-1/hepatocyte growth factor intracoronary injection fosters survival and
regeneration of the infarcted pig heart. J Am Coll Cardiol 58: 977–986.
Cardiosphere Cell Therapy for the Infarcted Heart
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25669